Anonymous Donors at Blood Donation Center (NUH) Clinical Trial
Aim: To identify HLA-A1101-restricted peptide epitopes derived from novel Oncoantigens
(URLC10, KIF20A, and CDCA1) applicable for Cancer Vaccine in Singapore.
Methods: The panel of candidate peptides are synthesized and tested for their ability to
induce peptide-specific CTL responses, in order to screen the peptide epitopes applicable
for the cancer vaccination. Briefly, peripheral blood lymphocytes (PBLs) derived from
HLA-A1101(+) healthy donors are taken and cultured in the presence of the each candidate
peptide with recombinant IL-2 for 2 weeks, and then, re-stimulated with dendritic cell
pulsed with the peptide following another 2 week culture. Thereafter, CD8(+) T lymphocytes
were negatively selected with CD4-magnetic beads from cultured lymphocytes and tested for
their peptide specificity employing enzyme-linked immunospot (ELISPOT) assay. These
conditions are completely performed in in-vitro system. Importance in medicine: If one could
identify the peptide epitopes from novel Oncoantigens, it is applicable for clinical trials
of cancer vaccination.
Benefits & Risks : There is no risk except for the matter of venipuncture in each
individuals.
The ideal target molecules for cancer vaccination are thought to be selectively expressed in
tumor cells, but not in the normal cells, with high frequent and homogenous expression
within tumor. We have proved that novel Oncoantigens, URLC10, KIF20A and CDCA1, have these
characters as ideal target molecules for the cancer vaccination and are highly expressed in
a variety of tumor type such as gastric, lung, and pancreas cancer. Since HLA-A1101
haplotype is most frequent in Singaporean, it is essential to indentify the
HLA-A1101-restriced peptides derived from these Oncoantigens to develop cancer vaccination.
n/a
Observational Model: Cohort, Time Perspective: Prospective